MedTrace Logo

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Conditions

  • Unresectable Stage III NSCLC

Interventions

DEVICE

Multiparametric Mobile Technology

Using a spirometer, an armband, and a tablet to collect data.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2022-01-27
Completion
2022-01-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381494 on ClinicalTrials.gov